Analysis of the efficacy of pretreatment regimen containing idarubicin in allogeneic hematopoietic stem cell transplantation for high-risk refractory leukemia
10.3969/j.issn.1674-7445.2020.02.009
- VernacularTitle:含去甲氧柔红霉素的预处理方案在异基因造血干细胞移植治疗高危难治性白血病中的疗效分析
- Author:
Haoyu CHENG
1
;
Yixin YANG
;
Fan YANG
;
Weijie ZHANG
;
Xinhong FEI
;
Yuming YIN
;
Jiangying GU
;
Qihang MAN
;
Jie ZHAO
;
Jingbo WANG
Author Information
1. Department of Hematology, Aerospace Center Hospital, Beijing 100049, China
- Publication Type:Research Article
- Keywords:
Idarubicin;
High-risk refractory leukemia;
Acute myeloid leukemia;
Acute lymphoblastic leukemia;
Pretreatment;
Allogeneic hematopoietic stem cell transplantation;
Recurrence;
Overall survival;
Disease free survival;
Cumulative recurrence rate
- From:
Organ Transplantation
2020;11(2):240-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of pretreatment regimen containing idarubicin (IDA) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-risk refractory leukemia. Methods A total of 116 patients with high-risk refractory leukemia who received allo-HSCT treated with 7 types of IDA-containing pretreatment regimes were enrolled in this study. The implantation rate of 116 recipients was summed up. The 2-year overall survival (OS), 2-year disease free survival (DFS), cumulative recurrence rate, recurrent mortality, transplantation related mortality (TRM), cumulative incidence of acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD) were statistically analyzed by Kaplan-Meier survival curve. Results All 116 recipients successfully implanted. The median follow-up time was 28 (7-70) months. Among them, 64 recipients survived, the 2-year OS was 55.2%, 2-year DFS was 51.7%, 2-year recurrent mortality was 23.3% and 2-year TRM was 18.1%. Among 116 recipients, 72 cases suffered from aGVHD. The 2-year cumulative incidence rate of aGVHD was 62.1% including 20 cases of grade Ⅲ-Ⅳ aGVHD, the 2-year cumulative incidence rate was 17.2%. Among 116 recipients, 59 cases presented with cGVHD. The 2-year cumulative incidence rate was 55.4%, of which the 2-year cumulative incidence rate of extensive cGVHD was 14.7%. Among 116 recipients, 30 cases recurred with a 2-year cumulative recurrence rate of 25.9%. Conclusions IDA-containingpretreatment regime has high safety and effectiveness, and can be used as an effective pretreatment regime for transplantation preprocessing in patients with high-risk refractory leukemia.
